Antonio Febbraro

Carboplatin Plus Paclitaxel Versus Carboplatin Plus Pegylated Liposomal Doxorubicin As First-Line Treatment for Patients With Ovarian Cancer: The MITO-2 Randomized Phase III Trial

Sandro Pignata, Giovanni Scambia, Gabriella Ferrandina et al. · Journal of Clinical Oncology · 2011 · 212 citations · Full text

Unresectable Locally Advanced Pancreatic Cancer: A Multimodal Treatment Using Neoadjuvant Chemoradiotherapy (Gemcitabine Plus Stereotactic Radiosurgery) and Subsequent Surgical Exploration

F. Polistina, Giorgio Costantin, F. Casamassima et al. · Annals of Surgical Oncology · 2010 · 168 citations

Pancoast Syndrome, Surgical Oncology, Pancreatic Cancer +7

Topotecan Compared With No Therapy After Response to Surgery and Carboplatin/Paclitaxel in Patients With Ovarian Cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) Randomized Study

Sabino De Placido, Giovanni Scambia, Giovanni Di Vagno et al. · Journal of Clinical Oncology · 2004 · 164 citations · Full text

Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial

Nicola Normanno, Anna Maria Rachiglio, Matilde Lambiase et al. · Annals of Oncology · 2015 · 145 citations · Full text

Capri Goim Trial, Medicine, Pathology +8

Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial

Fortunato Ciardiello, Nicola Normanno, Evaristo Maiello et al. · Annals of Oncology · 2014 · 116 citations · Full text

Translational Medicine, Oncology, Gene Mutation Status +11